Let's Get Honest! Absolutely Uncommon Analysis of Family & Conciliation Courts' Operations, Practices, & History

Identify the Entities, Find the Funding, Talk Sense!

Genzyme, BioEnvision, ImPath, Sanofi – New Strains of Fish in the Ocean of Commerce

with 8 comments

Yes, it’s disheartening reporting (from the front lines as well) what makes people broke and drives them homeless or close to it (particularly, federal policy and welfare reform with its diversions into Designer Family Curricula).

However, in looking at this policy one continues to run into some of the larger industries (corporations) running and directing the policy of our non-representative governments (US, state, county, regional, etc.).

See the list @ What Brings All These Companies Together in One Electronic Place and for One Cause?” (July 7 LGH post)… That question is still on the table; most of my comments these days are “spam.” However, there are other networks (like phone, email, etc.); the word is out.

This post is a bit of a wild ride, which is better than the straight path to poverty and drudgery, and narrating who paved the road… I think it shows there IS an alternate way to live, and one of the better ways to get there is to ignore the advice, and perhaps follow the career paths of people who are arrogant enough to believe they should be planning for the planet, and coaching people what kind of jobs to work, inbetween inventing and merchandising new technologies, raising capital for startups and then selling them and with the profit, starting up some more things, most of this related very, very (very very) closely to the healthcare and pharmaceutical industries, who are most likely to sponsor professorships, fellowships, centers of excellence at the university level, and all kinds of projects which might improve THEIR profits.*

(Don’t miss the part where a leading geneticist George Church (see Human Genome Project) is interviewed by a German magazine about the theoretical and technical possibility bring the Neanderthals back to life through DNA (and of a surrogate human mother). And where he figures, well, there’d need to be a cohort of them… This mindset probably wouldn’t be welcome in any welfare-to-work programs as a legitimate work-activity — creative thinking and inventing “disruptive technologies” which some of these below are called. In fact, in my experience, the extended gauntlet of the family courts is about THE best way to squelch any creative thinking — if one parent exhibits it, the other can simply get them labeled as an oddball or eccentric thinker, and next moment it’s — where are my kids? Thus while it’s not quite LEGAL to actually OUTLAW creative thinking or resourcefulness in single parents (or their exes), a lot of it can be screened out in the family law arena, preserving the status quo of “divorce” as a crime, and non-collaborative (with the ex) behaviors as a thought-crime close to it. ]]

[*And sorry about all those long opening sentences. I can’t reconstruct DNA, so apparently like stringing those ideas together in a sentence; and yes, that is a form of play…)

Particularly if one wasn’t born into the privilege and/or hasn’t hit the ground running from an early age…to end up at Harvard, Yale, etc. it might be good to look at the flip side of the social science research and demonstration fields one is constantly exposed to while going through the courts, custody, etc. matters….

How each of these corporations got started and what they are doing is downright inspiring and enlightening. It’s a history lesson — on the actual mutual-benefit factor, as opposed to the alleged public benefit factor, which sometimes turns out to be just myth. It takes money to keep the myths spinning, too — so like I continue to say, “follow the money” and “educate yourself.”

This Top section is just to brush some biotech language in front of our faces, maybe as an industry alert that, finding minimum-wage jobs for those on welfare may not be the best idea for them, at least if “income self-sufficiency” is the long-term goal… in THIS global corporate climate?

From “FierceBioTech.com (“The BioTech Industry’s Daily Monitor”) we see a Harvard Biological Chemist dive into the thrill-seeking team science environment of searching for things to help the Pharmaceutical companies come up with new drugs. Look at the startup funding, and the companions (not to mention the company names):

Prolific Harvard chemist Greg Verdine takes helm at Warp Drive
July 2, 2013 | By Ryan McBride

Professor Gregory Verdine has founded plenty of biotech companies, but Warp Drive Bio has become the first one he has ever helmed as CEO. After co-founding Warp Drive, which launched last year to discover natural product drugs, Verdine has taken over the chief executive role from Third Rock Ventures partner Alexis Borisy.

Based on Verdine’s original scientific idea, Warp Drive took off last year with a $125 million financing deal to mine bacterial genomes for drug compounds. Sanofi signed on as a funder and collaborator from the start, helping Third Rock and Greylock Partners to finance the drug-discovery effort. Borisy, who Verdine credits for the business plan behind Warp Drive, has become the startup’s executive chairman.

That whole article is fascinating; towards the end it mentions GlaxoSmithKline, Sanofi, and Novartis as companies willing to come “back to earth” in searching for great bacteria to test new drugs on. That’s where Warp Drive and a Harvard chemistry professor seem to come in.

Related, earlier this year (like, January), we learn about the Financial Power of Syndication:

UPDATED: Fueled by Sanofi, Warp Drive Bio takes off with $125M deal
January 12, 2013 by Ryan McBride

Biotech startup Warp Drive Bio has scored $125 million in financing from a syndicate that features the French drug giant Sanofi ($SNY) along with founding backer Third Rock Ventures and the VC firm Greylock Partners. More than just an investor in Warp Drive, Sanofi has an option to acquire the startup if the new company can hit certain goals in developing drugs found in microbial genomes.

With a brand new approach for discovering drugs from nature, Warp Drive aims to search the genomes of microbes for molecules that have the potential to target disease pathways that the have eluded all other attempts to do so. It’s the brainchild of Greg Verdine, a chemical biologist at Harvard and venture partner at Third Rock. His fellow founders include Harvard genomics pro George Church** and James Wells, who studies protein-to-protein interactions at the University of California, San Francisco. (“UCSF”)

“This is the type of early-stage, blue sky, innovative, transformative company that a lot of people are saying just isn’t getting created anymore,” Alexis Borisy, a Third Rock partner and interim CEO of the startup, told FierceBiotech. “But here we are. We have created it.”

James A. Wells vita (above) shows he started out at Genentech (one of the companies on “The List”) and in 1998 co-founded “Sunesis Pharmaceuticals. The Vita says more than I can summarize (not understanding all the terms).

Bio at “ACS” (American Chemical Society) blog. Notice that his work is aimed towards helping drug discovery, particularly it looks like cancer and inflammation.

James A. Wells, PhD, an internationally recognized biochemist and leader in the development of new technologies for engineering proteins and for identifying small molecules to aid in drug discovery, is a member of the prestigious National Academy of Sciences.

He joined UCSF in 2005 as the first holder of the Harry Wm. and Diana V. Hind Distinguished Professorship in Pharmaceutical Sciences, and has been the chair of the Department of Pharmaceutical Chemistry in the UCSF School of Pharmacy since July 1, 2008.

[[Harry Wm. Hind, 1939 graduate of UCSF School of Pharmacy, developed wetting solution for contact lenses that helped them becaome widespread, and more — lived to be 96 (til April 2012), more than $7.5 million to UCSF, see bio. He and partner (who left for the Navy in 1941) co-founded Barnes-Hind Pharmaceuticals. Later, in 1989, he worked to help his wife with shingles, and created Lidoderm anesthetic gel patch.]]}}

Wells is a professor in his home Department of Pharmaceutical Chemistry and holds a joint appointment as professor in the UCSF School of Medicine’s Department of Cellular and Molecular Pharmacology.

At UCSF, Wells’ research group focuses on the discovery and design of small molecules that trigger or modulate cellular processes in inflammation and cancer. Using small molecules and engineered proteins, the Wells lab is studying how enzymes known as proteases are turned on to cleave particular proteins in cells. The lab is focusing on one set of proteases, known as caspases, that kill virally infected or precancerous cells. These enzymes act as demolition experts and help us understand the essential protein struts that support life. Wells’ research spans the multiple disciplines of biophysics, cell biology, molecular biology, biochemistry and chemistry.

The Wells Lab at UCSF:

The Wells Lab is interested in designing proteins and small molecules that trigger cellular processes, in order to better understand and treat cancer and inflammation. Our research spans the multiple disciplines of chemical biology, biophysics, cell biology, molecular biology, enzymology, and proteomics. Our passion is to identify, activate, and inhibit critical signaling nodes to better understand how these drive responses such as cell death and differentiation.


George Church, Huffington Post 1/2013, denies that he’s looking for an “adventurous woman” to become surrogate for a Neanderthal, although apparently the possibility is not off the table…

Church says those reports are based on misunderstandings of an interview he gave the German magazine Der Spiegel. The publication had approached him to talk about his recent book, “Regenesis: How Synthetic Biology Will Reinvent Nature and Ourselves.”

Church said the idea of bringing back Neanderthals gets brief mention as a theoretical possibility, and the book refers to an “adventurous” woman merely to point out that the process would require a woman who no doubt would be adventurous.

“It said you’re going to need someone like that if you’re going to do it,” he said. “It’s certainly very different from taking out a want ad.”

Neanderthals were stocky, muscular hunters who lived in Europe and western Asia. They died out sometime after modern humans arrived in Europe, which occurred some 40,000 to 45,000 years ago.

Scientists have recovered DNA from Neanderthal fossils. Making a Neanderthal would start with putting such DNA into human cells. They would be used to make an embryo, which would be carried to term by a surrogate mother, Church said…. Such a process would face ethical questions involving respect for the mother and child, as well as safety issues, and it would also require societal approval, Church said.


I’ll say so. Right now, divorce isn’t receiving societal approval, and retaining contraception appears to be an uphill battle; can you imagine the custody issues if the surrogate wanted parental rights? What about foster care if the genomics genius couldn’t make time to be a good Dad?

Here’s that SPIEGEL interview, posted (in English) on SPiegel.de, also gives quick summary of Gregory Verdine’s co-founders. Several paragraphs in the table below — up to the line about, the importance of social diversity:

Interview with George Church: Can Neanderthals Be Brought Back from the Dead? [On-line Jan 18, 2013; cover story in “Der Spiegel” jan. 14, 2013]

In a SPIEGEL interview, synthetic biology expert George Church of Harvard University explains how DNA will become the building material of the future — one that can help create virus-resistant human beings and possibly bring back lost species like the Neanderthal.

George Church, 58, is a pioneer in synthetic biology, a field whose aim is to create synthetic DNA and organisms in the laboratory. During the 1980s, the Harvard University professor of genetics helped initiate the Human Genome Project that created a map of the human genome. In addition to his current work in developing accelerated procedures for sequencing and synthesizing DNA, he has also been involved in the establishing of around two dozen biotech firms. In his new book, “Regenesis: How Synthetic Biology Will Reinvent Nature and Ourselves,” which he has also encoded as strands of DNA and distributed on small DNA chips, Church sketches out a story of a second, man-made Creation.

SPIEGEL recently sat down with Church to discuss his new tome and the prospects for using synthetic biology to bring the Neanderthal back from exctinction as well as the idea of making humans resistant to all viruses.

SPIEGEL: Mr. Church, you predict that it will soon be possible to clone Neanderthals. What do you mean by “soon”? Will you witness the birth of a Neanderthal baby in your lifetime?

Church: I think so, but boy there are a lot of parts to that. The reason I would consider it a possibility is that a bunch of technologies are developing faster than ever before. In particular, reading and writing DNA is now about a million times faster than seven or eight years ago. Another technology that the de-extinction of a Neanderthal would require is human cloning. We can clone all kinds of mammals, so it’s very likely that we could clone a human. Why shouldn’t we be able to do so?

SPIEGEL: Perhaps because it is banned?

Church: That may be true in Germany, but it’s not banned all over the world. And laws can change, by the way.

SPIEGEL: Would cloning a Neanderthal be a desirable thing to do?

Church: Well, that’s another thing. I tend to decide on what is desirable based on societal consensus. My role is to determine what’s technologically feasible. All I can do is reduce the risk and increase the benefits.

SPIEGEL: So let’s talk about possible benefits of a Neanderthal in this world.

Church: Well, Neanderthals might think differently than we do. We know that they had a larger cranial size. They could even be more intelligent than us. When the time comes to deal with an epidemic or getting off the planet or whatever, it’s conceivable that their way of thinking could be beneficial.

[[**so they became extinct about 40,000 years ago in favor of humans moving into Western Europe because of ???]]

SPIEGEL: How do we have to imagine this: You raise Neanderthals in a lab, ask them to solve problems and thereby study how they think?

Church: No, you would certainly have to create a cohort, so they would have some sense of identity. They could maybe even create a new neo-Neanderthal culture and become a political force.

[[“Cohort:” more. Company for each other…]]

SPIEGEL: Wouldn’t it be ethically problematic to create a Neanderthal just for the sake of scientific curiosity?

Church: Well, curiosity may be part of it, but it’s not the most important driving force. The main goal is to increase diversity. The one thing that is bad for society is low diversity. This is true for culture or evolution, for species and also for whole societies. If you become a monoculture, you are at great risk of perishing. Therefore the recreation of Neanderthals would be mainly a question of societal risk avoidance.

[A whole other arena than the “responsible fatherhood healthy marriage” talk, isn’t it?]

[2010 New York Times article gives the flavor of Church and his background. If I’m reading it right, he MIGHT have been at least at one point raised by a single mother? At least, something happened when she married a physician, indicating yet another among the world’s notables of how such kids are truly at risk of being failures in life…like this one, who distinguished himself in the 1980s around gene sequencing, and has started several dozen companies. He wants to get the genomes of 100,000 people (or did in 2010>

Verdine’s vita shows plenty of pharmaceutical and other fellowships (Eli Lilly, DuPont, NIH, Searle, Roche, Zenecca Pharmaceuticals, Enanta Pharmaceuticals, plus Alfred P. Sloan et al.) He has a lab at Harvard, two-paragraph description gives an idea of the context, currently has himself, a lab administrator and about 18 Grad, Undergrad or Postdoctoral members:

The research interests of the Verdine lab lie in the emerging area of chemical biology.  We study biologic processes underlying growth and proliferation of human cancer cells, control of gene expression, and preservation of genomic integrity.  Our research has led to the invention of new and powerful approaches for the discovery of unconventional bioactive ligands termed “synthetic biologics” that have proven effective at addressing therapeutic targets previously considered “undruggable.”

Verdine and coworkers have elucidated the mechanism by which DNA methyltransferases catalyze epigenetic modification of the genome, as well as the structural basis for sequence specific DNA recognition by NF-κB and NFAT, master regulators of acute phase and immune responses and organ development.  Our work has illuminated the biochemical and structural basis for enzymatic recognition and removal of mutagenic damage in DNA.

OK, Greg Verdine as partner in Third Rock Ventures is also involved in startup Warp Drive Bio.

It sounds more than exhilarating.

Discovering drugs from microbes has its roots in the early days of the pharmaceutical industry, and it has produced many popular medicines such as the heart pill Lipitor, Borisy said. Yet Warp Drive is assembling a specialized search engine to hunt for molecules encoded in microbial genomes and make dipping into nature’s medicine chest far more efficient than past methods, he noted. Fast and cheap DNA sequencing has enabled groups like Warp Drive to assemble troves of genomic data on organisms of interest, Borisy explained, and the discovery work that the company is pursuing wouldn’t be possible without advances in sequencing genomes.

Warp Drive’s $125 million in committed capital, which the startup is expected to get in separate chunks based on the firm achieving certain goals, is enough to fund the company’s main R&D efforts for 5 years, Borisy said. The company, which is based in Cambridge, MA, has been incubating at the offices of Third Rock for the past two years. Its release says that $75 million of the total $125 million deal is equity investment.

In related news: Sanofi has struck a collaboration deal with another Third Rock-backed company, Foundation Medicine. Cambridge, MA-based Foundation announced the deal this morning, saying it plans use its genomic sequencing and analysis services to provide genetic biomarkers and companion diagnostics for Sanofi’s experimental cancer drugs. Sanofi is the latest of five drugmakers to form partnerships with the startup.

– here’s Warp Drive’s release
– see Xconomy’s story
– and Dow Jones Newswires’ report


(click title for the website, with maps of Boston and San Francisco. The dots on the maps are companies Third Rock has launched. Its motto is: Launching Extraordinary Healthcare Companies.

We are not just launching new healthcare companies – we are rapidly growing them, advancing pipelines to the clinic and developing new products. In just six short years, and during a period of time when early stage investing has been in flux, we have successfully raised more than $1.3 billion and invested in more than 31 companies to accomplish this mission. We truly believe that nothing is impossible.

[And it was only founded in 2007…) It kind of reminds me of ISIS Innovation Limited in Oxford, which is a wholly owned (by University of Oxford) subsidiary to professionalize technology transfer, i.e., turn those ideas into products — and money, and fast:

Isis was established by Oxford University in 1988 as its wholly owned technology transfer company.  Isis has developed substantially over the years in a number of phases, as the technology transfer activity has grown, and with the formation of Oxford University Consulting and Isis Enterprise.

Our mission is to be the leading international technology transfer organisation, to transfer technology and expertise from the University of Oxford, to deliver value to all our clients, and to maximise social and economic benefits in a commercial manner.

Isis manages the University’s intellectual property portfolio, working with University researchers on identifying, protecting and marketing technologies through licensing, spin-out company formation, consulting and material sales. Isis funds patent applications and legal costs, negotiates exploitation and spin-out company agreements, and identifies and manages consultancy opportunities. Isis works on projects from all areas of the University’s research activities: life sciences, physical sciences, social sciences and humanities.  Isis provides access to Oxford’s expertise and provides researchers with advice on commercialisation.

As these drug corporations are often (as well as R&D in technology and “disruptive science,” patenting genome search engines, and professionalizing the “ideation” process, while facilitating company and product launch for some very nice profits (it’s hoped) — they are ALSO funding different nonprofits specializing in the social science of human populations, i.e., to study and better regulate “us” (people who have major issues with the status quo of the court systems, and are struggling to survive it, or relatives of those who did NOT survive it), why not at least do them the favor of studying ’em back?

As I do this (unfunded) it seems that the playbooks some of us are supposed to use have almost no resemblance to the playbooks those promoting “Federal Designer Families” themselves use. They are on the corporate level; we are supposed to succeed through diligence, smarts, and above all, obedience to the rules (which the same — and this post shows a good example — don’t themselves obey, even in their own court, which is essentially capitalism, especially marketing to the sectors that the federal government controls (i.e., people in its systems).

Continued from post on “What are these companies doing in the same electronic place?” Here’s the list again, in different format (but same companies):

The Corporations:
3M Company~|~Accenture~|~ACT~|~Aetna~|~Aflac (INSURANCE, RIGHT?)Altria Client Services, Inc.~|~Amazon.com~|~American Electric Power~|~American Specialty Health~|~Amerigroup~|~AmgenAmplify ~|~ AON Corporation~|~Apple~|~Applied Materials~|~ARAMARK Corporation~|~Astellas Pharma – RxAstraZeneca Pharmaceuticals – Rx AT&T ~|~  Atria Senior Living ~|~


BAE Systems~|~ *** Bank of America ~|~  Barrick Gold of North America, Inc. ~|~ Battelle ~|~ Baxter – Rx ~|~ Best Buy Co., Inc. ~|~ Best Doctors ~|~ Biogen Idec ~|~ Blue Cross Blue Shield ~|~ BP America [BP=British Petroleum] ~|~  Bridgepoint Education ~|~ CenturyLink ~|~ Catamaran ~|~ Cerner Corporation ~|~ Chrysler ~|~ Cisco Systems ~|~ Citi ~|~ The Coca-Cola Company ~|~ The College Board ~|~ Comcast Corporation ~|~ CCA ~|~ CVS Caremark ~|~ Daiichi Sankyo ~|~ Daimler ~|~ Darden Restaurants ~|~ Deloitte [[!!!]] ~|~ DeVry, Inc. ~|~ The Dow Chemical Company ~|~ DTE Energy ~|~ Duke Energy ~|~ Education Management Corporation ~|~ Educational Testing Service ~|~ EMD Serono ~|~ Endo Health Solutions  ~|~ ESRI ~|~ ExxonMobil Corporation  [=Rockefeller] ~|~
***BAE Systems:”By navigating around this (web)site you consent to the use of cookies…”

Or, near it (alphabetically) “Barrick Gold of North America, Inc.” (from Barrick.com, “Operations“)

Barrick is the world’s leading gold producer. Our 2013 full year gold production guidance is 7.0 – 7.4 million ounces from a portfolio that includes some of the world’s premier gold assets. We have operating mines and advanced exploration and development projects located across the world, and large land positions on some of the most prolific and prospective mineral trends.


FMC Corporation ~|~ Ford Motor Company ~|~ Genentech [biotech] ~|~  General Electric Company ~|~ General Motors ~|~ Gilead Sciences, Inc.  ~|~ GlaxoSmithKline  [Rx] ~|~  Golden Living ~|~ Grant Thornton ~|~ GTECH ~|~ Hallmark Cards, Inc ~|~ Harley-Davidson Motor Company ~|~ HDR, Inc. ~|~ Hewlett-Packard Company ~|~ Hospital Corporation of America ~|~ Houghton Mifflin Harcourt Publishing Company ~|~ Humana ~|~ IBM Corporation ~|~ IntelIntuit ~|~ Johnson & Johnson ~|~ JPMorgan Chase & Co.  ~|~ Kaiser Permanente ~|~ Knowledge Universe ~|~ Level 3 Communications, LLC ~|~ Louis Berger Group ~|~ MAXIMUS ~|~ McKinsey & Company ~|~ Merck & Co., Inc. [Rx; see the Merck Manual] ~|~  Microsoft Corporation ~|~ Molina Healthcare, Inc. ~|~ Morgan Stanley [!!!]]  ~|~ Motorola Solutions ~|~ Mylan Inc. ~|~

~|~ Nestle Waters North America ~|~ NIC, Inc. ~|~ Nike ~|~ Norfolk Southern ~|~ Northrop Grumman (defense, right?)  ~|~  Novartis Pharmaceuticals USA – RxNovo Nordisk Inc. ~|~ Oracle USA Inc. ~|~ Pearson Education ~|~ Premier ~|~ Purdue Pharma – RxPfizer ~|~ The Procter & Gamble Company – RxPrudential Financial ~|~ RAI Services Company ~|~ Renaissance Learning ~|~ ResCare ~|~ 
Sanofi – Rx look it up! Global Healthcare ~|~  SAS Institute Inc. ~|~ SCAN Health Plan ~|~ Scholastic ~|~ Shire Regenerative Medicine ~|~ Sodexo USA ~|~ South Alabama Gas District ~|~ Southern Company ~|~ State Farm Insurance~|~ Target ~|~ TEVA Pharmaceuticals USA – RxTIAA-CREF   ~|~   Time Warner Cable  ~|~  Toyota Motor North America  ~|~ TransCanada ~|~ Truven Health Analytics  ~|~ Unilever United States ~|~ UnitedHealth Group ~|~ Union Pacific Railroad  ~|~  Verizon Communications ~|~  VMware ~|~ Walgreen Co. ~|~ Wal-Mart Stores Inc. ~|~ Weight Watchers International ~|~ WellCare Health Plans, Inc. ~|~ WellPoint, Inc. ~|~ Western Governors University

Any link — all those links — would lead to a history of corporate owners who are NOT living paycheck to paycheck, and do not get lectures like this — and are not the topic of lectures and discussions like this “The State’s Role in Supporting Marriage and Families“?

Anything seem a bit “off” here?

Coaching the Poor to THIS road to “Self-Sufficiency. . . .”

First of all, now that welfare law has been radically reformed (Family Support Act of 1988) which is to say, the thing is now in serious motion for the first time since about 1935, why not reform it some more — and more — and more?

**This 2003 report (Welfare Information Network, i.e. “WIN”) Vol. 7 No. 8, “The State’s Role in Promoting Marriage and Family Formation” details just how many sources of funding can be diverted into what the state feels is “optimal” for families — although maybe not all of them. Intro (notice the tone). light-blue background quotes the report, tan is my commentary, and after pointing out that THIS WIN policy is focused on the 4th (not 1st) purpose of TANF (welfare) — formation of two parent families — I included a a middle segment expounding on the passing admission in the report that “domestic or family violence” MAY be a factor in poverty, obviously a matter close to my heart (and life experience).

The formation and maintenance of two-parent families is one of the four overarching goals of the Personal Responsibility and Work Opportunity Reconciliation Act of 1996 (PRWORA).[see FN##] This goal reflects a growing recognition [See FN#] by researchers, advocates, policymakers, and service providers of the economic, emotional, and societal benefits of two-parent families, particularly for children. Research supports the belief that family formation and maintenance can play a crucial role in reducing many poor families’ dependency on public assistance. Marriage may not be feasible or desirable, however, when there is domestic or family violence, substance abuse, or criminal activity or when family formation results in financial hardship. [[Isn’t it nice that we are informed by the state under what conditions we should, or should not, form families — or be subjected to federally-funded indoctrination into forming families?]] Therefore, the welfare reform law gave states the flexibility to design programs and policies to encourage family formation as well as to support responsible parenting by both parents in situations where marriage is not feasible.

That last phrase says clearly that the states can support “responsible parenting by both parenting” even when one of them is so violent that family formation isn’t feasible or desirable!!!

{{FN# Sure, it was just a “growing recognition” = we are supposed to believe, or at least pretend we believe, it was “the light dawning” and not lobbying by special interest groups, like for example, the Children’s Rights Council or the National Fatherhood Initiative, etc.}}

{{FN## Yes it is ONE of the four goals of PRWORA. As seen here, and elsewhere, it is the FOURTH goal and not the first, which is “providing assistance to needy families so children can be cared for in their own homes, or in the homes of relatives.” But to some, Goal 4 pre-empts goal 1.
For example as early as 1999, in Oklahoma, some people had the sudden awakening that this TANF contigency fund had a surplus — why not divert that into Goal 4 promotion? I mean, PRWORA allowed it, technically speaking! That was the birth of the first “statewide” marriage promotion act, enriching probably thousands of providers, and I wouldn’t surprised if this included by millions of dollars, and putting “Public Strategies, Inc.” PR firm “on the map,” which it doesn’t seem to have been previously.

That particular link is a 2001 review of the “Welfare to Work” concept (testimony before House Ways and Means) and on p. 8, it too acknowledges “domestic violence” as one of six deterrents to finding “employment,” after already noting that obtaining employment doesn’t necessarily lead to leaving poverty. (which has been known all along, however that didn’t stop PRWORA from getting passed, or the preceding Family Support Act of 1988). Other deterrents include (in order listed): ~Health problems or disabilities; ~lack of high school diploma; ~(domestic violence); ~lack of job skills; ~substance abuse; ~limited English. Thus any recipient “having domestic violence” is labeled “hard to employ,” attaching the label to the victim, not the perpetrator.

It should also be apparent that ongoing DV can lead to health problems and disabilities — like physical injuries, or trauma issues up to the point of disability… While some abusers also specialize in curtailing access to education or marketable skills (a known factor), which might result in the “lacks job skills”, other are violent towards (women) that DO have education and job skills and have sought to exercise them within the relationship. That understanding of abuse is not really factored in when such a person ends up on the welfare in escaping (or, in having to continue to survive under welfare reform’s “how to co-parent with a criminal” policy, and simultaneously work and raise children, [domesticviolence.org, Common Myths) The violence and economic coercion is part of the put-down and control. Having to then go through the welfare system and being treated at most interfaces like an unemployable idiot if one questions a policy, or practice, or simply seeks straight answers on its functioning, is further insult. For example, I never could quite add up how, if child support enforcement was to REDUCE dependency on welfare, yet Child Support Enforcement = fatherhood promotion = ongoing custody battles resulting in Compromise of Arrears — how that reduces anyone’s dependency on welfare…}}

{{on the same topic, i.e., getting “welfare to work” when the cause of lack of work is domestic violence: from “Childwelfare.gov” “The Basics of Domestic Violence” (Chapter 3):

Domestic violence victims lose a total of nearly 8.0 million days of paid work—the equivalent of more than 32,000 full-time jobs—and nearly 5.6 million days of household productivity as a result of the violence.46

and (on the same page, under heading “Economic Coercion” — these characteristics are so very well known by many, and put a different light (ENTIRELY) on the social science discourse regarding marriage promotion as a SOLUTION to (rather than a CAUSE of) poverty among “needy families” and the paradox of trying to train us into the workforce, when it was the DV sometimes keeping us out of it, or trashing a work history:

~Preventing the victim from obtaining employment or an education;
~Withholding money, prohibiting access to family income, or lying about financial assets and debts;
~Making the victim ask or beg for money;
~Forcing the victim to hand over any income;
~Stealing money;
~Refusing to contribute to shared or household bills;
~Neglecting to comply with child support orders;
~Providing an allowance.

These same behaviors can continue after separation, thanks in large part to marriage promotion policy and the move for joint shared custody in the family courts, trying to include as many DV cases under the umbrella as possible).

[Commentary, con’td.]
I included the above passages to demonstrate that the government/s and agencies DO know that this family and domestic violence are common, affect women predominantly, are more likely to seriously injure or kill them, and includes economic coercion. Out of the other side of the same mouths (and this IS the same mouth as far as childwelfare.gov is concerned), they say, the problem isn’t DV, it’s fatherlessness. And they wonder why the public is dissociative? Imagine how the public not well acquainted enough with this system is to observe it, might think? Reality and theory don’t match, so they live in confusion, and go back to work to fund some more of the same programs…

{{Look at all the potential sources of reducing poverty (etc.) and improving humanity by marriage formation — how about reducing poverty by not withholding that much money (or extracting it) from the public’s energies and work efforts to start with? If I start a company, like from one of the lists above, can I have a seat at the federal policy-making table, or on MDRC (Below) as well, too, even if I’m not Rockefeller or Ford?}}

BACK TO the Welfare Information Network ARTICLE:

How can states fund initiatives to promote marriage and family formation? States may use TANF funds to provide services to couples and to create policies that promote healthy marriages and reduce the incidence of divorce. In addition, TANF funds may be used for fatherhood initiatives aimed at promoting greater involvement by fathers in their children’s lives. Under current law, federal funds may be spent on marriage and family formation activities targeted to a broader population and are not limited to low-income families. [See FN ###] However, state maintenance-of-effort funds are limited to programs for low-income families. TANF reauthorization proposals in the House and Senate include funds to promote marriage through research and demonstration projects, technical assistance to states, marriage education programs, and other initiatives.

In addition to funds available under current law and the potential for new funding streams in the reauthorization legislation, states may be able to use other federal and state funds or private monies to support activities related to family formation and marriage promotion. Other sources of federal funds for targeted initiatives include [bullets added]

  • the Social Services Block Grant (Title XX) for activities aimed at preserving and reuniting families;
  • the Promoting Safe and Stable Families Program for family support, parent education, and family reunification services;
  • the Administration for Native Americans for services to promote healthy marriage and responsible fatherhood among Native Americans; and
  • the Maternal and Child Health Block Grant (Title V) for abstinence-until-marriage programs.

In addition, some marriage promotion activities may be funded under the federal Head Start program as well as through fatherhood initiatives in the U.S. Department of Health and Human Services, the U.S. Department of Labor, and other federal agencies (see Welfare Information Network 2001). Other potential funding sources include the child support program, state children’s trust funds, state marriage license fees, and foundation grants. For more information, see Jarchow 2003.

FN ###. OK, WHY was this mentioned in some places to groups being solicited to apply for all kinds of funding to promote marriage funding — but not to the public at large, in very large letters, i.e., “MARRIAGE IS GOOD FOR US, THEREFORE WE ALL SHOULD FUND — THROUGH WELFARE — STATE PROMOTION OF MARRIAGE FOR EVERYONE, NOT JUST THE POOR, ALTHOUGH WELFARE LAW WAS ORIGINALLY DESIGNED FOR THE POOR.” This appears to have come up with later versions than th 1996 one, and a specific promotion by the CSEA (Child Support Enforcement Association — at various levels (national, regional, state) for the “evolving purpose” of Title IV-D activities. Attempts were made to force all NEW child support cases to be handled as Title IV-D (which is under, obviously, welfare) even when one parent was a millionaire. See Anne Stevenson’s 5 most dangers HHS programs for women and children (sidebar links)

That’s “Gradualism.” Get the foot in the door, to help the poor — and expand services to the rich as well, based on gender and marital status… How many Americans that even know about the fatherhood programs to start with (whose friends are in custody battles, or they are) — know that thes eprograms divert public money FROM the household where the children are TO the cause of getting the other parent to have more time with the child?

Sometimes I read this and wonder how many people would continue poor after separation or divorce if they’d not been, initially, encouraged to think in terms of buying and selling corporations, taught (as in, taught in school) about investments, and accounting — rather being instead encouraged to learn become, according to the sorting mechanism of the schools — either blue-collar workers or (if sorted out), white-collar professionals. I also wonder if more business weren’t taught at the K-12 level, there might not be an inherent interest in math (which is necessary to engage in it), and/or reading (which is helpful if one hopes to run a business) and history (which reveals the patterns of business in our country — unless it’s taught from dumbed-down and sanitized textbooks! (See “Diane Ravitch” et al.)

Basically, sounds like if it has “child, family, parent, or social services” on it somewhere — funding can be found. The Children’s Trust fund factor is one to watch. All the blue-color programs in last paragraph (as well as all bulleted federal programs, above) are strictly speaking — public money, which comes in part from everyone who contributes anything by way of taxes into the federal or states system, and prior generations who also did; not to mention as we can see, people who get married and pay the state license fees. The “and foundation grants” is a very vague reference to what is, in fact, a LARGE source of aid to this programming — and it represents private money. Foundations are usually formed from corporate wealth or family wealth with the goal of controlling to what use that money is put. (See Private Equity page, right sidebar).

Moreover — as we can see this nice “Welfare Information Network” 2003 issue above, helpfully tells groups so very many ways one can start sucking liquid gold (all but) off the federal faucets — i.e., where they might get some (hint, hint….) grants and funds to promote more “Marriage Promotion” projects — doesn’t it bring up the obvious question:

From where did the United States (federal departments, that is?) get all these billions to divert, in the first place? Why does Congress appropriate money for such programs? Why do state DHS directors think they’re such a great idea when their own constituents are raising hell about the programs, as happened in Kansas not long ago, when a secret convoy of family values people were flown in and met behind closed doors to discuss transforming Kansas into, well, something a little closer maybe to Oklahoma and it’s (in)famous Marriage Initiative?

Maybe our own government is just a little over-paid; perhaps if the government weren’t operating at such an astronomical profit (that it owns most of the infrastructure of the globe, at this point) — perhaps there’d be less poverty around? I mean, think about it!

By contrast the corporations on “the list” (top table)

This type of corporation (and those specific ones) prefer to fund the discussions about managing the poor, thereby framing, interrupting, and through sponsorship intercepting any truly open dialogue between the poor — or even normal, working, middle-class, un-incorporated citizens — and the government about the corporations. Any such conversations are colored by, who’s paying for them.

I cannot in one post, or even one blog, communicate how very saturated is governments at all levels by corporate influence to frame social science policy to manage the masses.

PROBLEM: Government itself is NOT reportable and prosecutable under the SEC for conspiracy to commit securities fraud and rob millions of dollars of profits from the shareholders, as were the executives of ImPath, below, were. Some got jail time, most got heavy fines, and properly so — because they conspired to lie to THEIR “public” (which bought and sold stock to help fund the company — not pad the executives payrolls when the company went under through their fraud….).

What do we do when the same activity occurs — only government is involved, and there’s no Government-run “Securities Exchange Commission” on its own trading of debt, securities, investments, etc. while they are also figuring out how many programs to benefit which corporations they can divert into social science demonstration pilot projects into? And when there is a literal teaching and research “institution” blending government (which is not reportable for securities fraud) and corporations (which aren’t likely to GET reported for securities fraud to the point they lose their government contracts) — what is the public, who foots the bill (while being researched and demonstrated upon, in addition to their own work lives) — supposed to do? Just go with the flow, lest they lose the corporate jobs? or someone simply opens the jail doors and lets the local community handle their own criminal element (after the same communities have been better disarmed, justified by the same criminal element….) ???

Another institution representing this blend to examine might be the “Center for Court Innovation” in New York — which is a joint project between “The Fund for the City of New York” and the Unified Court System of New York (between corporation and courts — private and government). Who funded the fund? Who funds the Courts (answer: should be, taxpayers — not private interests!).

The “WIN” article above is already ten years old — it’s from 2003.

I did not even discover any of this information, or comprehend is significance to me (and my children) personally, (see “Support This Uncommon Analysis” sidebar) until nearly 2009; in fact NO effort was made by any government entity to get this information to the average female (although there is outreach to males to enroll them in the various diversionary programs, such as compromise of arrears in exchange for starting a custody battle, or winning in one; or coparenting, batterers intervention, etc.) in the family courts!

But the policy began back in 1996, and the passage of the 1996 PRWORA definitely had some advance lead time. ERGO, I have to conclude that whatever else I was doing at the time (which I guess is a clue that I’m over 30 years old here), it wasn’t — understanding what my own government was doing, or who ran it. Nope, I was being a good citizen, nose to the grindstone, college, profession, working, serving and helping the local communities and schools.

This is exactly where most of the population is supposed to be — while fewer and fewer others actually set the rules and devise ways for them to be ignored or broken, etc., for example, if one of their own gets snared by mistake in the same nets actually designed for low-income population control.


These multi-million (or, billion)-dollar corporations then pour their wealth acquired, in part, by buying and selling parts of each other, raising capital for strategic positioning and targeting the US Government for contracts — and at times acquired by setting up monopolies via immoral and illegal means, or exploiting cheap labor, slave labor, etc. — and with their excesses, they can also afford to pour wealth into privately controlled foundations (reducing taxes as well) to run social science R&D on “how to reduce poverty” and lecture already poor people to do what they themselves, did not do to become wealthy.

And we’re not supposed to notice this?

This type of inquiry tells me why so many of these companies need to stay really closely connected to political leadership in particular of the Health and Human Services [HHS] stakeholders. “Stakeholders” are not generally considered the public, the public are future consumers, not a serious market force when forced-consumption is already available through the various courts (family, juvenile, dependency, mental health, drug, etc.) a significant Archipelago).

Out of a list of such corporations found on a website intended to influence government, at random I picked one, “SANOFI” which mentioned in its biographical material, “Genzyme,”

and looked up that Company. See recent post What Brings All These Companies Together in One Electronic Place and for One Cause?”, for the list.. (or, see top of this post)… There is much more information available on the companies in the post’s title here, some may have been posted already; hope you enjoy reading about it as much as I did learning about it.

Genzyme’s history of pioneering biotechnologists (how they did it) only to get bought out by Sanofi (HQ French?)seems to symbolize how “unreal” it is to have at the same time, a welfare system based on the United States only, of any sort. The corporations (and the US government) plays in the global sphere, but “we the people” who are NOT involved in international marketing and don’t choose to run biopharmaceuticals, or tailor our work lives to do business with, for example, the defense and military industries, are supposed to only consider the local spheres?

I’m also curious – -and angry — as a parent, to see how it’s many times not just innate drive or talent — but also positioning. You can learn by reading — a VERY early age; some of the CEO’s or founders of these major companies were run by people from wealth, who by association knew it’s better to buy and sell corporations, or at a minimum found them (find the technology, “just do it!”) than to become a hard and loyal worker at almost ANY trade which does NOT involve buying and selling companies, living off income from dividends, stock, etc.

Of these two entirely different mindsets — some inherited, some possibly learned through early hard times, some exemplified in immigrants to the US from countries at war — the one that produces is more wealth is the one NOT recommended by the institutions funded by that same wealth. In other words, if it’s not exactly an apartheid, it’s tending in that direction — sorting people by profile to keep them in their assigned spheres of activity — some, work hard at “these jobs” and hope that works out for you long term; we, on the other hand, will collaborate to make sure it doesn’t occur to you or your children, how business and government actually lock hands to lock some up, lock others “out” and at all times make sure we have adequate systems for “lockdown” in case of lone, alienated terrorists, or mass civil unrest.

Any number of situations (political, social, geographical, or by-birth, i.e., one’s race, one’s gender, one’s Daddy and Mommy, and where they were in society, who they were connected to, etc.) which can affect what a person applies and brings to the table in energy, talent, smarts, motivation and determination.

However we are in a time when the engineering of society, enabled by the internet and other computer-based technologies (including BIOtechnologies, most of which couldn’t happen without the prior invention of the computer, either for the the R&D, or the advertising and fund-raising for the R&D), WIDENS the gaps and NARROWS the controllers. And to me, the responsible thing is for more of us to understand more of that situation.

We have, for example, a nationalized public school system that is a public disgrace; it has trouble turning out kids who are literate and socially responsible, let alone competitive with other countries in science or math. Kids are getting pregnant, raped, drugged, and sometimes even killed at or around their own friendly neighborhood schools. They are learning military-style terms, like “lockdown” or weapons search, and arbitrary authority, as well as how to form gangs.

Traditional Public Schools are in many ways a microcosm of the managed society: expensive to communities (compared to other forms available) and unionized on the front end, but when it comes to what’s coming out the other end, including in what condition the children and young people are — the word is often alienated, class-segregated, values-indoctrinated, and being taught that the most important thing around is where they are on some bell curve. They are then well-prepared for further indoctrination and management in either courts, prisions, or the corporate workplace. Children and Youth in these schools are then also a captive audience for all kinds of consumerism (i.e., “TeenScreen” which was tied into then-Governor Bush’s TMAPP and (2003ff, no longer president), “New Freedom Mental Health Commission” types of policies.

For a laundry list of this, see list of “Accomplishments of CCHR

Those terms can be looked up and some of them have been blogged. I am speaking as a parent, and I have taught in a variety of schools throughout my lifetime, until the course through the family courts cut that part of my life out.

Properly speaking, in any area, a School District usually is a component unit of government. Say “school” to a person on the street, or a parent who’s not actually employed by a school district, and any number of ideas will come back, including what we need to do to improve them and make sure they get more funding.

How many would even think to understand (after having read the “Transmittal letter” of their local, county’s “CAFR”) that school districts ARE an arm of what we call “government” and as such, they are a tax-exempt business, an employer, a real estate owner (or leaser), and a source of income for innumerable industries and businesses, including the substantial textbook development business, software industries like “BlackBaud, Inc.” (who also serviced Domestic Abuse Intervention Programs, “DAIP” in Duluth, MN — and last I heard, helped make some multi-millionaires (Marc E. Chardon), and half-owner of a soccer? team in South Carolina. School Districts don’t pay corporate taxes — they provide a large client base for corporations that do. School Districts are part of government. They can also sue and be sued, including suing other parts of government (sample: June, 2013, LAUSD vs. Los Angeles County and City of Los Angeles (in Court of Appeals) over, looks like, who gets the pass-through for property tax increases through redevelopment projects. Or something similar). Over money… what else!

Wikipedia on LAUSD (the 2nd largest public school district (2nd only to NYC) in the country and the second largest employer ( to the County itself) IN Los Angeles County, it is governed by only a seven-member board, and has this kind of reputation:

The LAUSD has a reputation for extremely crowded schools with large class sizes, high drop-out[9] and expulsion rates, low academic performance in many schools, poor maintenance and incompetent administration.[10][11] In 2007, LAUSD’s dropout rate was 26 percent for grades 9 through 12.[12] Bond issues and ambitious renovation programs have not uniformly eased these conditions.[13] As part of its school-construction project, LAUSD opened two high schools (Santee Education Complex and South East) in 2005 and four high schools (Arleta, Contreras Learning Complex, Panorama, and East Valley) in 2006.[14]

I just learned it has its own police force; it was only “Unified” in 1961 (i.e., K-8 unified with 9-12, more centralized control) and soon after sued to desegregate in 1963.

CALPERS, the largest public pension fund in the world (I heard, doublecheck) was set up initially as far back as 1931. It is a major player. However, if you look up any county’s “CAFR,” it will specify whether there is a school district as a “component unit” of the county — or there is not.

So if we perhaps want a good checkpoint for how “government” is working, we should take the schools for at least one example.

To pretend (nationally) this doesn’t have anything to do with the pharmaceutical or biotech industries, and alternate forms of population management, at this point, is simply immature – in my opinion.

So, part of schools is managing (uplifting?) poor people, especially poor black people (who for many years had to also deal with segregated public housing, going back to the early 1920s — with Rockefeller involvement — such that the alternate short title for the Civil Rights Act of 1968 was the Fair Housing Act. ALL of this relates to public MANAGED finances, off a public-contributed platform, including funds obtained through the Public Health and Welfare Act (i.e., 42 U.S.C., including but not limited to, the Social Security Act), which relates to corporate wealth — real estate development, etc.

I often have the issues of Food Stamps and Child Support on my mind, because there have been times (in recent months and even this past year) I was both hungry and completely without cash flow (others have commandeered resources actually due ME, which also cuts off my ability to further help my own children who have aged out of the family court system. However, it took the further knock-out punches of the psychology and “conciliation” based court system to completely dismantle mother/child relationships, in favor of “father” relationships. What a waste of dollars, time, and talent, to try and turn “goats into sheep,” and make sure that “the poor, you always have with you.” (Bible references in case that was missed).

The family court system, as it now exists incentivized by federal fundings and diversions from “welfare” — is a social hazard to women and children who are now, and have always been, indispensable to the efforts of the men who still rule Congress, most religious institutions, one of the oldest and largest religious CORPORATIONS on the planet (Home Base, the Vatican City) and who care for and live with the wounded and shell-shocked veterans, sometimes amputees — which each round of wars kicks out.  That is, unless it’s so unsafe to live with the veterans that they become homeless instead.

Someday, people are going to start BELIEVING that Philanthropic Foundations whose wealth was built from family corporate businesses (many times, mostly privately held) are NOT benign in this country.  All of the country was warned in the mid 1900s, but this knowledge gets lost in the information deluge.   We have to find a way to take the USA out of a state of permanent, Executive-Ordered state of war emergency, making our own citizens “aliens” in their own land, or at least the land they were born in after the Indigenous (native) Americans, who weren’t called Americans — had been cleared mostly out of the land by genocide or enclosure.


[Organizations coach the poor on how to succeed in life by obtaining employment]… While schmoozing and strategizing a completely different path to not just self-sufficiency, but ongoing wealth.




The company was started by Sheridan Snyder, George M. Whitesides[4] and scientist Henry Blair** in 1981 and is primarily devoted to finding drugs that would cure enzyme deficiency conditions that were essential to human survival and which usually afflict a very small percentage of the world’s population. Drugs used to treat such conditions are considered to be “orphan drugs.” In 1986, the company went public, raising $27 million.

A look at GEORGE, HENRY, and SHERIDAN follows.


(**George M. Whitesides was born August 3, 1939 in Louisville, KY. He received an A.B. degree from Harvard University in 1960 and a Ph.D. from the California Institute of Technology (with J.D. Roberts) in 1964. He was a member of the faculty of the Massachusetts Institute of Technology from 1963 to 1982. He joined the Department of Chemistry of Harvard University in 1982, and was Department Chairman 1986-89, and Mallinckrodt Professor of Chemistry from 1982-2004. He is now the Woodford L. and Ann A. Flowers University Professor.

Research Interests
Physical and organic chemistry, materials science, biophysics, complexity and emergence, surface science, microfluidics, optics, self-assembly, micro- and nanotechnology, science for developing economies, catalysis, energy production and conservation, origin of life, rational drug design, cell-surface biochemistry, simplicity, and infochemistry..)

[[awards, too many to list, but start with Alfred P. Sloan scholarship, 1968.  Genzyme is 1981 — see above timeline.  Classic career, and very successful, scientist.  Worked with DARPA, NASA, you name it.  You keep them happy — give them the money, the labs, the colleagues — and they will produce, and produce, and produce, they love the work.  Here’s a photo of him from a Harvard Wyss Institute.  Check out the description


Henry Blair ALSO (below) should also be looking pretty happy; the first link I showed, he’s Chairman of Dyax (formerly founded by him in 1989 as Biotage) and his base salary is $647K, but all things considered, it’s $1.4 million. I should probably mention, he’s in biopharmaceuticals…).  Article from TuftsNow talks about  Blair:

“I had a great science teacher in prep school from whom I took chemistry, biology and physics. He really instilled in me an interest in science, and biology in particular,” says Henry Blair. Photo: Kathleen Dooher

A Flair for the Business of Medicine

By Bruce Morgan
April 12, 2012

In the mid-1960s, Henry Blair signed on as a research technician at the New England Enzyme Center, a first-in-the-nation facility housed at Tufts Medical School. Blair was a bright young man from Pittsburgh who had a knack for reinvention.

Photo caption:  “I had a great science teacher in prep school from whom I took chemistry, biology and physics. He really instilled in me an interest in science, and biology in particular,” says Henry Blair. Photo: Kathleen Dooher

In 1981 he co-founded Genzyme Corp. out of an old clothing warehouse at 15 Kneeland St., adjacent to the medical school. “When we started I had a desk and a bunch of clothes racks and hangers,” Blair recalls.

Genzyme grew into one of the most successful biotechnology companies on the planet, employing some 10,000 people worldwide. The company’s signature product, Cerezyme, is a cure for Gaucher’s (go-SHAY) disease that costs patients up to $200,000 a year. Last spring, on the 30th anniversary of its founding, Genzyme was acquired by the French pharmaceutical giant Sanofi

Aventis for $20.1 billion.

Blair, who left Genzyme in 1987 to found Dyax Corp. (among other biotech companies), has taken a step back from business life and divides his time between homes that he is remodeling in eastern Maryland and on Cape Cod. He is an emeritus member of the Board of Advisors to the medical school.

You must have been good at teaching yourself what you needed to know.

That’s essentially true. The reason I never graduated from college is I never got through the requirements—for a language, and everything else. All I wanted to do was study science, and that was not the way to get a degree back in those days. But I was taking courses as I worked, some at Tufts, some at BU, Harvard and UMass.

. . . .
You’ve launched a number of companies. Would you say you’re a restless person?

I think my attention span is fairly short. But I’ve been involved with Dyax for over 20 years now, and I stayed on the board of Genzyme until about four years ago.

Do I not keep squawking about that? Educate Thyself – -Love to Learn and Experiment!

However it doesn’t hurt to have some prep school encouragement for placement and ending up in a good place for this to start with.. and some networks in place.  Read on….

and, last but not least:


[[If time would permit, I’d tell more about co-founder Sheridan Snyder’s (privileged) background, and how he is a serial entrepreneur from almost Day 1, after going to an elite private, boarding, college-prep school in the Princeton, NJ area — which school, banded together in ca. 1974 to establish their future “eliteness” in The Eight Schools Association, not to mention the Ten Schools Association (overlap of 7 out of the 8 in “The 10”) not to mention the “G20” association which is rather more inter-continental in scope.  In other words, OUR kids are gonna succeed:

Lawrenceville is a member of the Eight Schools Association, begun informally in 1973–74 and formalized in 2006. Lawrenceville is also a member of the Ten Schools Admissions Organization, founded in 1966. There is a seven-school overlap of membership between the two groups.[2] Lawrenceville is additionally a member of the G20 Schools group. ….

Can you spell, mutually exclusive, and kinda sorta Ivy-League like?  Keep the commoners out… or there goes the neighborhood:

It began informally during the 1973–74 school year and was formalized in 2006 with the appointment of a president and an executive director. The ESA member schools are:

There must be unanimous agreement among ESA schools before its membership can be expanded, and no new school has been admitted since 1974.[1] By further institutionalizing the group in 2006, the eight member schools “ultimately aim to forge ties in a similar fashion to the Ivy League, but with a focus on academics and other extracurricular activities rather than just athletics,” according to a 2008 article in Andover’s newspaper, The Phillipian.[2]

Speaking of boys’ and girls’ social networks, Genzyme co-founder “Sheridan Snyder” (among 3 people) went from privileged prep school to  (Univ. Virginia/ degree in Romance Language). Wikipedia says he was a member of “SPE Fraternity.”  Whaddaya know, after reading all about Genzyme, Yours Truly (LetsGetHonest) went ahead and googled “SPE Fraternity” only to read that among all the specially fraternizing and “sorority-izing” groups in place since 1852 [Pre-Civil War, much?] , and organized in 1934 into IFC (the InterFraternityCouncil at UVA) in 2011 a special statement on the “SPE Fraternity,” claiming they are NOT in the “in” crowd but an Independent group; their membership in the IFC was terminated or putting student health at significant risk  [“numerous risk management violations”]!  (hover cursor or click through).  Admittedly, that was a few generations after the Genzyme guy was there…

Statement on “SPE” [Sigma Phi Epsilon] Fraternity: Read Here
“The fraternity system at the University of Virginia has a long-standing tradition of excellence in leadership and service. Since 1852, fraternities have been an integral part of each student’s quest to become a well-rounded individual within the University community. The wide variety of interests and personalities within the system provide unparalleled camaraderie and support, which last much longer than a brother’s stay at the University.

Established in 1934, the Inter-Fraternity Council (IFC) governs twenty-seven social fraternities. The Governing Board, which consists of nine Executive Committee members and seven at-large members, represents the core of the IFC. The Inter-Fraternity Council works with the members of the Presidents’ Council in an effort to continue to strengthen the fraternity community at the University through progressive policies, programs and education.”

Fraternities in Limbo: A look into the fates of Brotherhoods on the Grounds

(4/29/2011 by Nick Eilerson) in the Cavalier Daily (serving UVA community) talks about hazing in general.  … Then there was Sigma Phi Epsilon (Fall 2009) who was so bad they gave the guys 30 days to find other housing and forbid them from organizing for 3 years, after some incidents that were “life-threatening” enough (including “Car Bash”) that basically parents gave them no choice.  The national organization was embarrassed.

UVA ends Pledge Period Early, Joins Growing Wave of Change (The Daily Progress, 4/6/2013)

They’re getting tired of Greek week producing too many hospital visits resulting from hazing.  The Univ. President cracked down on that IFC:

The University of Virginia has joined a growing list of schools that have taken public steps to control fraternity pledging or ban it outright.

UVa Dean of Students Allen Groves ordered the 31 fraternities that compose the school’s Inter-Fraternity Council to end pledging by 6 p.m. Sunday. He earlier set the date for Saturday but announced a one-day extension Friday.In a letter to Greek alumni Thursday, Groves cited “colorable reports of hazing and misconduct,” including excessive alcohol consumption and “other behavior that threatens the health, safety and well-being of … students.”

The reports come two months after the Inter-Fraternity Council received a dressing-down from Groves and university President Teresa A. Sullivan over a rash of alcohol-related hospital visits by students coinciding with Greek rush week. …

The culture of passive acceptance and a “boys will be boys” approach to pranks and rituals designed to bond pledges and also to test their mettle is dissipating, as a generational shift in attitudes means more students who are subjected to line-crossing behavior are also more likely to speak up, experts said.Which reminds me that “hazing” and “frats” are good models of how to form gangs whose partnership is based on loyalty sufficient to do illegal, idiotic and destructive things, possible traumatic bonding, the basis for a future life of business referrals and helping raise capital for friends.  Of course Yale’s “Skull and Crossbones
” crowd would rather trump SPE, I imagine…

More on Sheridan G. Snyder:

Loyalty has its perks — the Univ. of Virginia got a Tennis Center named after this gentleman, in addition to its 1931 center which was a gift from Lady Astor, “a member of British Parliament.”


THERE’S no question we are dealing with someone who “gets things done.” After Genzyme (which went public then was bought out by bigger fish in the ocean), you can see from his LinkedIn (which shows, strangely, “1 connection”) fully three “company websites” and that all three are privately held.

  • Honors: Officer of the British Empire (OBE), 2004
  • Honorary Doctor of Law, LLB, University of Dundee,Scotland, 2002
  • State of Virginia, Biotechnology Lifetime Achievement,1999

The guy has a BA in Romance Languages, 1958!! His first company (1964) did high-speed envelope inserting machines. He understands business, apparently! (See Frat days?) Looks like he’s provided more of the business and “fraternizing” aspects.

Anyhow regarding the Genzyme, apparently its first medical task was finding an Rx for Gaucher’s disease:

In 1981, Mr. Snyder founded Genzyme and served as Chairman/President/CEO. Genzyme’s business focused on enzyme deficiency diseases. It first produced diagnostic enzymes for victims of Gaucher’s disease, a rare chronic disorder causing enormous enlargement of the spleen, a change in skin pigmentation and bone lesions. It afflicts 10,000 young Hasidic Jews each year.[3] It currently employs 10,000 people worldwide, with approximately $3.6 billion in revenues, with a market valuation of $20 billion. Genzyme (NASDAQ:GENZ) is the largest private employer in Boston, Massachusetts. In 1986, Mr. Snyder initiated the first sale of Genzyme stock shares (Initial Public Offering).[4]  

[Having gone public in 1986, Genzyme digests InPath in 2004 (simultaneous with Snyder getting an Order of the British Empire?  Are they investing in Genzyme?:]

Genzyme acquired several of Impath’s laboratories and cancer-testing technologies in May 2004, after Impath sought Chapter 11 bankruptcy protection.  I’ll make this section a different background-color:

Published: March 02, 2004 New York Times

The Genzyme Corporation, which last week agreed to buy Ilex Oncology Inc. for about $1 billion in stock to enter the market for cancer treatments, said it was the lead bidder for the cancer testing business of Impath Inc. The company bid $215 million in cash for Impath’s physician services unit, said Dan Quinn, a spokesman for Genzyme. The purchase may be completed in the second quarter, subject to a bankruptcy court’s approval, he said. The acquisition would be Genzyme’s third in six months as growth slows for its best sellers, the enzyme-replacement therapy Cerezyme and the dialysis drug Renagel. Impath, with $127 million in debt, sought protection from creditors in September.

Drug sales were down, so Genzyme went looking for distressed companies to buy and to increase its leverage and market access… PRWIRE news release, after the purchase

Genzyme Completes Acquisition of IMPATH Cancer Testing Unit —————— Further Expands Company’s Presence in Oncology

CAMBRIDGE, Mass., May 3 /PRNewswire-FirstCall/ — Genzyme Corporation
(Nasdaq: GENZ) announced today that it has completed its purchase of IMPATH
Inc.’s (IMPHQ.PK) Physician Services business unit
, a leader in the rapidly
expanding market for oncology testing. Under the asset purchase agreement,
Genzyme acquires IMPATH’s Physician Services unit and other assets for
approximately $215 million in cash. These assets will become part of the
Genzyme Genetics business. Genzyme will provide financial guidance on the
impact of the transaction to the corporation after completion of its purchase
accounting review.

The acquisition of IMPATH’s Physician Services unit, highly regarded for
its oncology medical expertise and quality service, contributes to Genzyme
Genetics’ extensive test menu for oncology, prenatal and reproductive
medicine. Through acquisition of this unit, Genzyme obtains a leading array
of oncology diagnostics in solid-tumor and blood-based cancers, a strong team
of board-certified anatomic and clinical pathologists with extensive
experience in oncology testing, and laboratories in New York City, Phoenix and
Los Angeles. Genzyme will maintain operations at these facilities.

As part of this transaction, Genzyme also acquires IMPATH’s Analytical
Services unit, which includes a laboratory approved by the U.S. Food and Drug
Administration that provides clinical trial testing services to biotechnology
and pharmaceutical companies in support of the evaluation of new drugs. The
Analytical Services unit is located in the Los Angeles facility.

The addition of IMPATH’s cancer diagnostic business — together with
Genzyme’s planned acquisition of ILEX Oncology announced this past February —
will significantly expand the company’s presence across the entire continuum
of oncology patient care, from diagnosis to treatment. These transactions
will create opportunities for Genzyme to develop and offer innovative products
and services that lead to more accurate diagnoses and more effective
treatments for cancer patients.

Yep. Public offerings help raise money, but then shareholders get to vote — and you can be bought or sold on the open market by other bigger fish in the sea. In this case, it looks like ImPath did all the scientific groundwork, and after they did this, Genzyme simply bought them.

33% of Impath shareholders were a little displeased with this and objected. The sale went through; here are their objections:

Genzyme wins key Impath Divisions” 4/2004, in “The Daily Deal”

Genzyme Corp. won court approval Wednesday, March 31, to pay $215 million in cash to buy nearly all the assets of Impath Inc.

Judge Prudence Carter Beatty in U.S. Bankruptcy Court for the Southern District of New York in Manhattan gave the go-ahead on a deal that’s aiming to close by the end of April, said George Davis, New York debtor counsel at Weil, Gotshal & Manges LLP.

The sale gives Genzyme the Impath Physician Services Inc. and Impath Analytical Services Business divisions of the New York cancer testing company. Genzyme must also assume a limited amount of liabilities. All 10 objections to the sale were resolved prior to the hearing, Davis said. ….

An official equity committee was formed after disgruntled shareholders alleged that Impath had not been adequately weighing the option of a stand-alone reorganization. The shareholders feared that Impath might hold a fire-sale despite its financial turnaround significantly enhanced its value.

“We’re not challenging the sale because we’re satisfied that it has been properly marketed,” said John Jerome, Philadelphia counsel for the equity committee at Saul Ewing LLP.

But Impath’s shareholders weren’t always so happy with the company’s sale plans.

Dissident shareholders, who owned 33.78% of Impath’s stock, formed an ad hoc equity committee and then won approval to make it official. They had wanted Impath to study a stand-along reorganization after the company began generating positive cash-flow soon after its filing.

Impath’s stock price plunged 85% before its filing after announcing it was under investigation by the Securities and Exchange Commission for accounting irregularities.

The company’s price dipped to $1.85 at filing before climbing above $5 four months later and the shareholders thought there might be more in it for them under reorganization. The price was trading Wednesday between $5.55 and $5.80 after hitting $7 on March 1.

The Dark Report” discusses how such buyouts may lead to decline in quality as local pathology groups might be closer and more responsive to the populations they serve; and unable to compete.

ImPath was “fire sale” goods because it had to file for Chapter 11 Bankruptcy. In fact, the SEC filed suit against several of ImPath’s financial leadership for financial fraud — i.e., faking to shareholders that it was doing well, when in fact it was failing.

Which just goes to show how hard it is to find good help:

(From Wikipedia Impath):
In September 2005 the United States Securities and Exchange Commission took action against former CEO Anuradha Saad and her colleagues, alleging fraudulent accounting.[1] The same month Saad pleaded guilty to two counts of soliciting proxies containing false statements.[1] It was also alleged that Saad improperly charged $120,000 in personal expenses** to Impath.[1] On Tuesday, May 30, 2006, the former president and chief operating officer of Impath, Richard P. Adelson, received a sentence from district court judge Jed S. Rakoff.[1]. It’s pretty serious stuff (see SEC announcement, 2006). One guy was sentenced to 3.5 years in prison and restitution of $50over cursor or click through…

[**Furniture, art, and beauty expenses. She got a few months in jail and a slap-on-the-wrist fine ($6,900) for $120K in fraud. The shareholders lost ImPath….Starting to sound like government itself…] Search for “Impath” here on Sep. 2005 SEC news. Four officers were permanently enjoined from acting as the officer of another public company. Related criminal charges were filed.

Here’s the Criminal Indictment in Southern District New York, “USA v. Anuradha D. Saad and Richard P. Adelson,” Count One, “Conspiracy to commit Securities Fraud, File False Reports with the SEC, and Falsify Books and Records” [posted a justice.gov, it doesn’t have the case number typed in, but is STAMPED “05 CRIM. 325” and “Judge Rakoff” and as Electronically Filed 3/28/2005; …]

WELL, after getting Impath, Genzyme decided to get BioEnvision.

Genzyme had a sub-license from Bioenvision to market clofarabine in North America. On May 29, 2007 Genzyme made a tender offer to purchase Bioenvision for $5.60 per share. On October 27, 2007, a majority of shareholders voted to approve Genzyme’s acquisition.[6] In 2007, CEO, President, and Board Chairman Henri Termeer, earned a salary of $2.5 million, and non-cash compensation worth $129 million.[7]

Bioenvision Shareholders Approve Acquisition by Genzyme Corporation [That press release isn’t dated, but it must’ve been somewhere around the end of May, 2007 — see my next quote, another press release of a Bioenvision shareholder protests Genzyme “low-balling” Bioenvision’s stock.]

Genzyme Corporation and Bioenvision announced this afternoon that Bioenvision stockholders have voted to approve the acquisition of the company by Genzyme at a reconvened special shareholder meeting in New York. The transaction will be effective tomorrow. Bioenvision shares have now ceased trading and the company will be delisted from Nasdaq.

Fifty-six percent of Bioenvision’s issued and outstanding shares of common stock and preferred stock, voting together as a single class on an as converted basis, supported the merger. This represents approximately 67 percent of the total shares voted.

With its acquisition of Bioenvision, Genzyme takes a significant step in enhancing its existing oncology business by gaining the exclusive, worldwide rights to clofarabine.

[[note — horizontal lines in next article are my way of FORCING wordpress to keep the paragraph breaks in….]

Investor hits Genzyme’s plan to buy Bioenvision
Firm calls the offer lowball, ‘ill-timed’
By Stephen Heuser, Globe Staff | May 31, 2007

Genzyme Corp.’s planned takeover of New York cancer drug maker Bioenvision Inc. has already hit a bump: A key Bioenvision shareholder is calling the deal a lowball offer and digging in against it.

On Tuesday, just hours after Genzyme said it had reached an agreement to buy Bioenvision for $354 million in cash, investor Steven Rouhandeh sent a fax to Bioenvision’s board calling it an “ill-timed” deal that didn’t fairly value the company. His fax was disclosed in a filing yesterday.

Rouhandeh’s firm, SCO Capital Partners LLC , owns about 7 million shares of Bioenvision, or 13 percent of the company. …

The deal requires half of Bioenvision’s shares be tendered to Genzyme within the next 19 days. Rouhandeh doesn’t control enough of Bioenvision’s stock to block the sale, but if his complaint galvanizes other shareholders, it could make the deal more expensive for Genzyme.

Genzyme and Bioenvision’s boards have both already agreed to the sale. The deal would give the Cambridge company full control of a cancer drug called clofarabine , to which the companies currently share the rights. Genzyme sells the drug in the United States as Clolar, and Bioenvision sells it elsewhere in the world as Evoltra .

Clofarabine is approved only to treat children with one type of recurring leukemia, but the companies have been testing its effectiveness against other cancers. Genzyme expects the drug eventually to be approved for wider use.

In his letter to the board, Rouhandeh suggested Genzyme was swooping in while Bioenvision’s stock was at a low. The company just diluted its share value to pay for new clinical trials, he said, and is awaiting a decision on whether Evoltra will be approved to treat another type of cancer. If the company wins approval, the news would sharply increase its value.

“The company just traded off a 52-week low, so it seems odd that buyout negotiations would be taking place in this time-frame,” Rouhandeh wrote.” [etc.]
Stephen Heuser can be reached at sheuser@globe.com.
© Copyright 2007 Globe Newspaper Company.

So, Cambridge, Mass-based Genzyme was hoping to go more global with a certain drug it already shared rights with; Genzyme got US rights and BioEnvision got the rest of the world (same drug, different name, apparently they’d also co-developed it.) About 2007.

More news from the Genzyme Wikipedia page, ca. 2009-2010 — just a little contamination in Massachusetts (and Belgium) plants, not to mention bits and pieces of non-drug material start showing up in the drugs…. Oops…. See “Contamination” section of the Genzyme “Wiki” page. But no one died, and it’s for treatment of rare diseases, so the FDA let it stay on the market….

In June 2009, Genzyme’s Allston, Massachusetts plant was shut down to correct a viral contamination (Vesivirus 2117). A similar event had occurred in 2008 at the Geel, Belgium facilities. By April 2010 it had restarted operation at diminished capacity.[9]

In November 2009, fragments of stainless steel, rubber, and fiber-like material were discovered in some of Genzyme’s drugs. The FDA found these materials in Cerezyme, Genzyme’s treatment for Gaucher disease, a rare genetic disorder that can lead to life-threatening organ damage. The FDA is permitting the drug to stay in the market, due to a lack of adverse events, and a critical need for the product.[10]

Anyhow . . . . further reading on ImPath (or Genzyme) should prove interesting. It’s a biotech world these days. And in the ocean of commerce, the plankton of job-seekers are the most common food source; further up the chain, bigger fish run in schools sometimes, or predator becomes prey, etc. Among them all swim vast whales of government funding platforms which are either hospitable, or inhospitable, to fishies coming to them for help, or shelter.

WOW. I just did some more (a lot more) reading on some of the corporations under Gregory L. Verdine’s name — most of which lead back eventually to some of the ones on my “list” — which I note includes “AstraZeneca.” Part of his background includes Zeneca Pharmaceuticals Award for Excellence. Even the Wikipedia history of Zeneca (A UK firm) and its merger with Astra (Swedish) is fascinating. I looked (see comments) at someone on the board of directors of Enanta Pharmaceuticals (again, see comments to this post) which tied back to a highly-placed German doctor — who also sits on the board of quite a few pharma companies (at least two in San Diego, if I remember it right) and Hoechst AG (new York) which is a name most, I think, might recognize.

Hoechst (the “Zoominfo on Dr. Ernst Gunter-Afting says) was acquired by “Aventis.” Can you spell SANOFI-AVENTIS?

This brief page from a UK-based site, Venture Navigator, describes WHY the pharmaceutical market is so very profitable — once you get in — and how this probably also attracted the biotech firm. It’s well-written and makes sense:

This case study is a recent history of the pharmaceutical industry based on all of Porter’s five forces. If you would like to try this assessment on your own business then try out our Porter’s 5 Forces Assessment [to read, must sign up for the site, checking its TOC and allowing the University of Essex, I guess, to put some cookies on your computer….).

In the 1970s and 1980s, the average profit margin (as a percentage of revenues) of the Fortune 500 pharmaceutical companies was two times greater than the median for all industries in the Fortune 500. Each drug introduced between 1981 and 1983 ‘made at least $36 million more for its investors, after taxes, than was needed to pay off the costs to develop it . . . Such profitability was two to three percentage points greater than for comparable industries, even after factoring in the risks of new drug development’. Nearly two decades later, in 1999, the industry was still a star. The pharmaceutical industry ranked at the top in all three of Fortune magazine’s measures of profitability: return on sales, return on assets and return on equity. What made the global pharmaceutical industry so profitable for so long? Why has its profitability remained so strong, and will the industry remain so attractive?

I do NOT think that the pharmaceutical and biotech industries, and their history (including to industrial chemical manufacturers in the late 1800s early 1900s) can be ignored. These guys are obviously giants — and they stay closely related to governments because governments deal with health care, with regulating patents (protecting profits once the patent is obtained) and much more. The article explains it well….

For “zeneca” — a branding company invented the name. See Wikipedia.

Here’s another article (PRwire newsrelease) on Gregory L. Verdine (see near top of the page) as scientific advisor to “Variagenics” — which is licensed by Harvard. Mentions another individual who is “Novartis Professor of Biology at (MIT) Center for Cancer Research.”

(Massachusetts Secretary of State)
Entity Name Identification Number Old Identification Number Principal Office
Address, City, State, Zip, Country
VARIAGENICS, INC. 043182077  000000000  60 HAMPSHIRE ST., CAMBRIDGE, MA  02139  USA 

(including prior names, mergers, etc.).

Here’s commentary (from the UK) on a 2003? merger of Cambridge, MA “Variagenics” with a Sunnyvale, CA based “Hyseq” prophesying possibly a little bit of doom (“the end of the line”) for them. From “Nature Biotechnology

The main problem for Variagenics, though, was that it simply failed to secure enough deals with pharmaceutical companies in pharmacogenomics. Although the company does now have a collaboration with Novartis (Basel, Switzerland) on its prostate cancer drug, Gleevec, the expectations at the company’s IPO back in July 2000 were that the company could secure one big deal per quarter. That never happened. Shea believes that Variagenics may have been a victim of its early arrival in pharmacogenomics. “The received wisdom is that pharmaceutical companies will pay for unproven technology in drug discovery,” he says, “but in drug development they want to buy services.” He hopes that by taking Hyseq’s clinical program forward, the newly merged company may be able to provide the essential commercial proof of concept.

Hyseq had its own difficulties, most prominently in regard to cash. Despite two bridging private rounds of funding since August 2001, Hyseq came into the merger with just over $4 million in cash—enough for a month and half at the sort of burn rate the company had been used to in the first 9 months of the year. The company had lost nearly 80 employees (40%) over the year, largely in the area of agricultural gene discovery when its collaboration with BASF Plant Science was terminated.

Written by Let's Get Honest|She Looks It Up

July 17, 2013 at 7:25 pm

8 Responses

Subscribe to comments with RSS.

  1. I looked up some of that Third Rock Ventures (“Life Science Venture Capitalism) company in Massachusetts. The secretary of state says it’s a Delaware Company, formerly “LST Partners, LLC.”

    I usually look up street address. Theirs shows with two different suite #s for “principal place of business” — one is 29 Newberry, Suite 301, Boston, Mass — and the other, Suite 401.

    Here’s some badmouthing about a property management firm at the #301 address (dates??). Apparently J.B. Property Solutions was sold during the owner’s divorce, to Premier Property Solutions.
    Jeff Birenbaum and Jessie Popovich got divorced and that’s part of the history:

    “November 15, 2010
    J.B. Property Solutions is now Premier Properties-STAY AWAY. My association has been using Premier Properties previously known as JB Property Solutions for the past three years [[do the math — since 2007…]] and they have been TERRIBLE. They nickel and dime you for everything, the quality of their work is sub par and they add no value to your association. They managed our association for over a year without even having a key to our building. They also charged us an additional month and took six weeks to refund our operating account making the association delinquent on all of our bills. Don’t listen to their lies, stay as far away as possible.”


    Principal Places of business get interesting and a friend of mine taught me to look them up. I’ve made it a habit, usually leads to more valuable information (although value varies with the situation for sure). When the street address of a private nonprofit is in the local county courthouse, then it’s time to wake up, fast.

    BOSTON, MA  02116 USA ISS SUPPLY COMPANY, INC. 000991741   
    BOSTON, MA  02116 USA ISS SUPPLY COMPANY, INC. 000991741   
    BOSTON, MA  02116 USA ISS SUPPLY COMPANY, INC. 000991741   
    BOSTON, MA  02210 USA ISS SUPPLY COMPANY, INC. 000991741   

    The address says “c/o J.B. Property Solutions” 311 Summer Street.”
    JB was Voluntarily Dissolved on 3/29/2013.
    Premier Property Solutions, was formed in 2010 (at the same address).

    Entity Name Identification Number Old Identification Number Principal Office
    Address, City, State, Zip, Country
    PREMIER PROPERTY SOLUTIONS, LLC 272437506  001027095  311 SUMMER ST., BOSTON, MA  02210  USA 

    I just searched on Greegory L. Verdine’s companies, including “Enanta Pharmaceuticals” (formerly by another name) with itts many dirrectorss.

    Onne of those directors was obviouslly German,, so I loooked up Dr. Ernst-Gunter Afting, and think this might be a little extra posting…..


    “Dr. Afting, 69, has served as a director since 1996. From 1995 until his retirement in 2006, Dr. Afting served as President and Chief Executive Officer of the National Research Center for Environment and Health, GSF-National Research Center for Environment and Health GmbH, a governmental research center in Munich, Germany. From 1993 to 1995, he served as President and Chief Executive Officer of Roussel UCLAF, Paris, a pharmaceutical company. He was also a member of the board of directors of the Pharmaceutical Division of Hoechst Group from 1984 to 1993 and was chairman and Chief Executive Officer of the Divisional Pharmaceutical Board of Hoechst from 1992 to 1993. Dr. Afting was a member of the Advisory Committee on Science and Technology to German Chancellor Helmut Kohl from 1996 to 1997 and from 1996 to 2005 was a member of the German National Advisory Committee on Health Research to the State Secretaries of Science, Technology and Health. Dr. Afting has been a member of the medical faculty at the University of Goettingen since 1985. Dr. Afting currently serves on the boards of Intercell AG, Enanta Pharmaceuticals, Inc., and Olympus Europa GmbH. He received his Ph.D. in Chemistry and M.D. from the University of Freiburg/Breisgau, Germany.””

    WWell,, you could look and look and look, anyhow, HBM Healthcarre Investments (Cayman IIslands) owns or owned about 8..69% of the Enanta Stock, per an SEC filing. Don’t count on my tyyping,, as you can see the letters are ddupiccating.


    Gunther-Afting is also on the board of SSequenom (Corp.. HQ — San Diego).
    http://www.sequenom.com/Home/About-Us/Board-of-Directors.. Can yyou sspell PrreNatal and Opthalmaaloogical??

    “”Sequenom, Inc. (NASDAQ: SQNM) designs, develops, manufactures and markets innovative technology, instrumentation and  tests that target and serve discovery and clinical research, and clinical molecular diagnostics markets. Applications include  translational research, oncology, agricultural genomics and in vitro diagnostics for prenatal and retinal disorders.

    Technologies employed include mass spectrometry and second generation DNA sequencing. The company’s proprietary MassARRAY® system is a high-performance mass spectrometry based DNA analysis platform that efficiently and precisely measures the amount of genetic target material and variations. The system delivers reliable and specific data from biological samples and from genetic target material that is only available in trace amounts.

    The company was founded in 1994 and employs over 550 employees worldwide. Sequenom is headquartered in San Diego, CA.

    Sequenom is committed to improving healthcare through revolutionary genetic analysis solutions.”

    Let's Get Honest

    July 17, 2013 at 7:31 pm

  2. Variagenics (only interesting to me in re: the Gregory L. Verdine/Harvard connection) was the subject of a securities class action lawsuit over its IPO:


    Conclusion: Other actions have been filed making similar allegations regarding the IPOs of more than 300 other companies. All of these have been coordinated for pretrial purposes as In re Initial Public Offering Securities Litigation, Civil Action No. 21-MC-92.

    According to a Press Release dated 12/06/2001, the complaint alleges violations of Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 and Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

    On or about July 21, 2000, Variagenics commenced an initial public offering of 5 million of its shares of common stock at an offering price of $14 per share (the “IPO”). In connection therewith, Variagenics filed a registration statement, which incorporated a prospectus (the “Prospectus”), with the SEC. The complaint further alleges that the Prospectus was materially false and misleading because it failed to disclose, among other things, that: (i) the Underwriters had solicited and received excessive and undisclosed commissions from certain investors in exchange for which those Underwriters allocated to those investors material portions of the restricted number of IPO shares issued in connection with the Variagenics IPO; and

    (ii) the Underwriters had entered into agreements with customers whereby the Underwriters agreed to allocate shares to those customers in the Variagenics IPO in exchange for which the customers agreed to purchase additional Variagenics shares in the aftermarket at pre-determined prices.

    SIC Code: 8731
    Sector: Healthcare
    Industry: Biotechnology & Drugs
    COMPANY/ISSUER NAME: Variagenics, Inc.
    COMPANY WEBSITE: http://www.variagenics.com
    Florence Rozen, et al. v. Variagenics, Inc. et al
     COURT: S.D. New York  DOCKET NUMBER: 01-CV-10999
     JUDGE NAME: Shira A. Scheindlin
     DATE FILED: 12/06/2001  SOURCE: Business Wires
     CLASS PERIOD START: 07/21/2000  CLASS PERIOD END: 12/06/2000
     TYPE OF COMPLAINT: Complaint (Unamended and Unconsolidated)

    Los Angeles Times (actually, ‘Bloomberg News”) article about the Hyseq/Variagenics acquisition shows just how far down the latter’s stock had dropped and how quickly (in two years?) From $14/share to $0.96 a share. The purchase got it up to $2.22 a share:

    Hyseq Agrees to Purchase Variagenics
    November 12, 2002 | From Bloomberg News
    Hyseq Inc. of Sunnyvale agreed to buy Variagenics Inc. for about $55.9 million in stock to accelerate development of a drug to dissolve blood clots and develop other products. Hyseq would exchange about 1.65 shares for each Variagenics share, the companies said. That values Variagenics, based in Cambridge, Mass., at $2.22 a share, more than double Friday’s closing price of 96 cents. Shares of Hyseq fell 27 cents to $1.08 on Nasdaq.

    Let's Get Honest

    July 17, 2013 at 7:37 pm

  3. […] it up, showing how they eat up each other, excrete pieces, re-assemble and in general, do business: Genzyme, BioEnvision, ImPath, Sanofi — new strains of fish in the ocean of commerce.. Except for the biotech aspect, they're not really new — they are all doing business based on […]

  4. […] Genzyme, BioEnvision, ImPath, Sanofi – New Strains of Fish in the Ocean of Commerce [2013, 07/17] […]

  5. […] Genzyme, BioEnvision, ImPath, Sanofi – New Strains of Fish in the Ocean of Commerce [2013, 07/17] […]

  6. Great Article. Thanks for the info. Does anyone know where I can find a blank “Courts Answer Form” to fill out?


    August 7, 2015 at 12:05 am

    • Sorry it took so long to approve this comment. Sounds like you may have been posting on more than one place; did you get an answer? Check on the county courts website (or maybe state, i.e., judicial council-approved forms) they may have some that could be downloaded. Or just keep asking; someone locally might know. Without a context, I don’t have an answer.

      Let's Get Honest

      August 18, 2015 at 5:14 pm

      • Or if there is a pro bono legal services group (nonprofit) in the area.

        Let's Get Honest

        August 18, 2015 at 5:15 pm

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: